"Dancing molecules," the promising new treatment for acute spinal cord injuries developed at Northwestern University, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).
Biorce is exactly the kind of pioneering company we're here to back. They're combining deep sector expertise with cutting-edge AI to solve what truly matters.
The Neuralink chip, known as the Link or Telepathy, was implanted by surgeons at the University of Miami Miller School of Medicine, marking the first such procedure at a Miami hospital. The chip allows RJ to wirelessly control a computer, as demonstrated by his ability to play video games using only his mind.
The study highlighted that combining structured exercise with chemotherapy can improve overall health outcomes in colon cancer recovery, showing that exercise should complement medical treatments.
The ARCAD database is a wonderful example of collaborative efforts around the world to create large patient-derived datasets that enable expanded research opportunities beyond the initial question addressed in the original design of a clinical trial.
This funding round gives us the momentum needed to take the next big step in our journey, launching U.S. clinical trials and supporting our European commercialization strategy.
Six years after Caroline Criado Perez's bestselling book 'Invisible Women,' women continue to be underrepresented in clinical trials, with significant disparities in research focus.
Health experts are raising alarms about the significant under-representation of women in UK clinical trials, emphasizing the urgent need for more focused studies on women's health.
Azalea Vision's first closing of its â¬15M Series A funding round enables the clinical trials of its revolutionary eye care technology, aimed at FDA approval.
The freeze of federal research grants to Harvard disrupts critical oversight of medical studies, impacting the rights and safety of research participants.
Glycomine's progress towards delivering the first disease-modifying therapy for a rare genetic disorder was bolstered by a $115 million Series C funding round.
âNow, Britain used to be so much better than this, but weâve taken our foot off the pedal,â said a government spokesman, emphasizing the urgent need for improvement in the clinical trial setup process.